StacyE.CroteauMD

Hemophilia & Bleeding Disorder

Director Hemophilia/VWD Program, Boston Children's Hospital Assistant Professor of Pediatrics, Harvard Medical School

Dr. Croteau is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
300 Longwood Ave
.
Boston, MA 02115
Phone+1 617-355-8246

Fax+1 617-730-0641

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2011 - 2014
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2007 - 2011
The Warren Alpert Medical School of Brown UniversityClass of 2007

A Gene Transfer Study for Hemophilia A Start of enrollment: 2017 Jan 26
Completed
Phase 1, Phase 2
Roles: Contact

PubMed

21 citations
Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium
Julie Jaffray, Brian R. Branchford, Neil A. Goldenberg, Jemily Malvar, Stacy E. Croteau
The Journal of Pediatrics. 2021-01-01
90 citations
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
Lindsey A. George, Paul E Monahan, M Elaine Eyster, Spencer K. Sullivan, Margaret V Ragni
The New England Journal of Medicine. 2021-11-18
17 citations
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
Rebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, Tiffany Chang, Sammy Chebon
Blood Advances. 2022-12-27

Lectures

Advances in Hemophilia A: Expert Guidance and Practical Case Discussions
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Risk Factors for Hospital-Acquired Venous Thromboembolism in Children: Findings from the Children’s Hospital-Acquired Thrombosis (CHAT) Registry
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Thrombotic Events with NovoSeven® RT in Approved Indications Are Rare (0.2%) and Associated with Older Age (>= 65 y), Cardiovascular Disease, and Concomitant Use of aPCCs
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Gene Therapy Can Transform Life for People with Hemophilia. But Some Patients Don’t Want ItJanuary 29th, 2023
BioMarin: Depressed Price Due to CRL, Major Catalysts AheadJune 1st, 2021
Gene Therapy for Hemophilia: Progress and SetbacksOctober 20th, 2020
Join now to see all